Individualized growth hormone substitution with normalized IGF-I levels does not stimulate the renin-angiotensin-aldosterone system.

What Was Tested

This controlled clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To study the effects of individualized recombinant GH substitution, aiming at normal circulating IGF-I levels, in GH-deficient adults on blood pressure, the renin-angiotensin-aldosterone system (RAAS), natriuretic peptides and urine free cortisol.

Who Took Part

The study group was 17 subjects.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Eighteen patients (11 males and seven females) with GH deficiency participated.

For comparison the researchers also prospectively evaluated 17 matched control subjects.

How the Study Was Run

Open study with control group.

Blood pressure and heart rate, circulating levels of IGF-I, plasma renin activity (PRA), immunoreactive active renin (IRR), angiotensin II, aldosterone, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and 24-h urine aldosterone and urine free cortisol levels.

What Was Measured

The subject headings attached to it are Anthropometry, Atrial Natriuretic Factor, Blood Pressure, Heart Rate, Human Growth Hormone, Hydrocortisone and Insulin-Like Growth Factor I.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 17 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2002 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.